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ABSTRACT:
Context: Wide spread use of misoprostol is increasingly commoner in our obstetrics and gynaecological practice, 
most especially for Induction of labour in spite of its serious associated risks of maternal and fetal complications
Objective: To determine the use of Misoprostol for induction of labour among the Obstetricians in the West 
African sub region.
Methodology and settings: During the October 2007 pre examination workshop of the West African College of 
Surgeons (FWACS), Faculty of Obstetrics and Gynaecology 42 examiners responded through structured 
questionnaires on the use of misoprostol for induction of labour (IOL) in their institutions of practice. 
Results: About 91 % admit using misoprostol for IOL with only half (50%) having written protocols for labour 
induction with misoprostol. Almost all (93%) prefer the vaginal route for the administration of misoprostol and 
about 74% do not use misoprostol for those with Caesarean section scar compared to only 19% who do. 
Misoprostol is used for cervical ripening and control of post partum haemorrhage among 24.4% and 50% of the 
Obstetricians respectively. The commonest complications encountered were Fetal distress, uterine rupture and 
uterine hyper tonus among 54.8%, 52.4% and 45.2% of the respondents.
Conclusions: Misoprostol use was high with yet serious complication occurring among those using it for IOL. 
Despite the manufacturers and other regulatory agents warning against its use in pregnancy because of serious 
maternal and fetal complications, misoprostol use for IOL is widespread. A regulated use of this drug especially in 
pregnancy is advocated.
INTRODUCTION
reports and meta analysis including Cochrane 
database, ACOG, British Royal college of 
Obstetrics and Gynaecology and other regulatory 
4agencies when used for IOL .  Misoprostol 
compared to other induction agents is observed to 
be stable analogue, it can withstand tropical 
5conditions, hence does not need refrigeration . It s 
also cheap and easily available across the counter, 
and  misoprostol  may play an important role in 
Obstetrics and Gynaecology practice in poor 
resource settings like ours where maternal 
mortality is high  and other prostaglandins 
6
preparations are prohibitively expensive . For 
now “off” label use of misoprostol will continue 
Misoprostol is a synthetic prostaglandin 
E1analogue developed and marketed as Cytotec 
by GD, Searle Co, Chicago, IL for the treatment of 
gastric and duodenal ulcers as well as the 
1prevention of NSAIDS associated ulcers in 1985 . 
2 The suggestion by Margulies that Misoprostol 
might be effective for labour induction generated 
interest that increased it's used in our Obstetrics 
and Gynaecological practice. Fifteen years after its 
introduction the manufacturers of the drug Searle 
pharmaceutical company warned against its use in 
pregnancy because of its arbotificient property and 
formally wrote a letter to the American College of 
Obstetrician and Gynaecologist (ACOG on august 
rd
23  2000 stressing on the dangers of this drug in 
pregnancy and its risks both to the mother and 
3.
fetus when used for induction of labour (IOL)  In 
spite of the acceptable clinical evidence of other 
induction agent (Pitocin), wide spread “off” label 
use of misoprostol became increasingly common 
among Obstetricians, in spite of its risks from 
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in our hospitals until such a time when our 
regulatory agencies will approve/license its use 
for IOL. 
This study was undertaken to determine the 
protocol and use of misoprostol for IOL and 
associated feto-maternal complications among 
the Obstetricians in the West African sub region.
METHODS
During the October 2007 Faculty of Obstetrics 
and Gynaecology of the West African College of 
Surgeons (WACS) fellowship examination fourty 
two examiners spread across 22 training 
institutions were issued with structured 
questionnaires to determine the use of misoprostol 
for IOL in their respective institutions. 
Information pertaining to unit (written) protocol, 
type and source of misoprostol, the minimum and 
maximum dose relating to parity and routes of 
administration of the drug. Also information 
pertaining to the used of misoprostol in patient 
with previous caesarean section, and other 
indication of misoprostol use in our units were 
obtained.
The data was analysed using SPSS statistical 
package version 11.0 and test of significance was 
determined using Chi square test.
RESULTS
Fourty two Obstetricians and Gynaecologists 
spread across the 22 WACS accredited training 
institutions in the West African sub region 
responded to the structured questionnaires, 30 
(71.4%) have written protocol for IOL in their 
institutions as shown on table I. Majority of the 
respondents (90.5%) were using Misoprostol for 
labour induction in their units, but only half (50%) 
of this have written protocol for IOL with 
misoprostol. Both Oxytocin and misoprostol were 
used by 30 (71.5%) of the Obstetricians. but 
expectedly about 31(73.8) still have reservation 
to use misoprostol to induce labour in those with 
Caesarean section scar compared to only 8 (19.0) 
who have no such reservation.
The route of administration and dosing regiment 
relating to parity is illustrated in table II
Almost all the Obstetricians 39(92.9) use the 
vaginal route for the administration of 
misoprostol IOL only 2.4% uses the rectal or oral 
route. About 66.7% of the Obstetricians prefer to 
use 50ug as a minimum dose to commence IOL 
for Primigravidae compared to only 19% who use 
a lower dose of 25ug, while for Multipara 50% 
prefer to use 50ug as against 42.9% who 
commenced them with lower dose of 25ug. 
Cumulative dose of up to 400ug were used for 
primigravidae as against 200ug as maximum 
cumulative dose for Multipara with as many as 
half (49.9%) of the Multipara receiving dose not 
exceeding 100ug compared to 31.9% of 
primigravidae.
Twenty two (54.4%) had written protocol for 
cervical ripening, while 19 (45.2) do not have. 
59.5 take the decision for both cervical ripening 
and IOL at the consultant level as against only 
2.4% who said its taken at the level of the 
resident, 38.1 of the respondents said the decision 
to use misoprostol could be decided at the level of 
both the residents and the consultant. This was 
shown on table III. The use of misoprostol or 
Foley's catheter and misoprostol and sweeping of 
the membrane are the popular methods for 
cervical ripening as practice by 33.3% and 33.1% 
of the Obstetricians  
The commonest complications were Fetal 
distress and uterine rupture experienced by 
54.8% and 52.4% of the Obstetricians in their 
practice respectively, while uterine hyper tonus, 
maternal pyrexia and still birth was reported to 
have occurred among 45.2%, 31% and 28.6% 
respectively.
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TABLE I: 
Protocol for IOL and misoprostol used Written 
protocol for IOL
                 Response               number                           % 
 
                 Yes                          30                               71.4 
                  No                          12                                28.6 
  
Written protocol for IOL with misoprostol 
                  Yes                         21                                50 
                   No                         21                                50 
                                                 ______________________ 
Misoprostol used for IOL  
                  Yes                        38                                90.5 
                   No  3                                 7.1 
                   N/R  1                                 2.4 
                                               _______________________ 
What do you use for IOL in your institution? 
                  Misoprostol 8                                 19.0 
                  Oxytocin  4                                  9.5 
                   Both  30                               71.5 
Misoprostol used with previous caesarean section 
                 Yes   8                                   19.0 
                  No   31                                 73.8 
                  N/R  3                                   7.2 
 
TABLE II: 
Route of administration and Dosage for 
misoprostol 
Route                             number                                      % 
Oral    1                                          2.4 
Vaginal   39                                       92.9  
Rectal    1                                          2.4 
N/R    1                                          2.4 
42                                        100  
 
Dosage regime in relation to parity
2 2                                                X = 32.714   P = .018      X = 24.781  P = .037        
*Cumulative dose of misoprostol given in multiple of 50ug 6hourly
TABLE III: 
Protocol for cervical ripening and other 
indications of misoprostol used Written 
protocol for cervical ripening
Response                          Number                               % 
Yes                                          22                                 52.4 
No                                           19                                 45.2 
 N/R                                         1                                   2.4 
             42                              100 
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Dosage (ug)                             Parity
Minimum                         Primigravidae (%)                 Multipara %)
5                                        8         19.0                     18        42.9
50                                       28   66.7                        21    50
100                                       3  7.1                          0             0
N/R        7.1                         3 7.13         
________________________________________________
 
42        100     
                    
42                100
X2 = 48.142   P = .007       X2 = 35.783  P 
= .023        
Maximum                        Primigravidae (%)  Multipara (%)
25   
       
1                    2.4                            3       7.1  
50  
      
4                    9.5                            9           21.4
75                           
      
3                    7.1                            0        0
*100                        
      
5                  11.9                            9           21.4 
*150 3                   7.1                              3            7.1
*200       
   
12                
  
28.6                             8        19.0
*250                   1                   2.4                             0            0
*300 2                   4.8                             0            0
*400 3                   7.1                             0       0
N/R       8                  19.0                           10          23.8
42                 10        42             100 
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Decision for cervical ripening and IOL
Method of cervical ripening
TABLE IV: 
Complications encountered with the used of 
misoprostol
DISCUSSION
The  use of misoprostol for induction of labour 
among  Obstetricians in West African sub- region 
is appreciably high reaching up to 90.5% 
prevalence, which is much higher than reported in 
a randomised study of 46% prevalence among 
Obstetricians and Gynaecologist in Brazil, 
7Jamaica and United States of America , this 
appreciable use might have been encourage by 
institutional studies in the sub-region which lay 
credence to its efficacy and other physical 
5, 6, 8, 9-11
advantages over other induction agents . 
Despite this widespread use, institutional 
protocol for its use in IOL is only found in about 
50%.  One third of the obstetricians still use both 
Oxytocin and misoprostol for IOL in their 
respective units
The general reservations for its use in those with 
previous caesarean section scar of  73.8% is not 
unconnected with the fear of uterine rupture 
observed  and cautioned by other regulatory 
3, 12 -16.bodies in other part of the world
The generally preferred route of administration of 
misoprostol for IOL among the Obstetricians was 
the vaginal route with 92.9% compared to oral, 
rectal and sublingual routes of only 2.4% 
17prevalence. Toppozado  reports that the vaginal 
route has success rate in a shorter interval as 
18
compared to oral route, while Bartusevicius , in a 
randomised controlled trial observed that 
sublingual 25ug and vaginal route 50ug has 
similar efficacy.
Significant number of our obstetrician 66.8% 
prefer to commence IOL for primigravidae with 
50ug compared to 19% who commenced with 
25ug, but there was no much significant 
difference between those that use 25ug (42.9%) 
and 50ug(50%) for IOL in Multipara. Though 
there was no clear safety advantage, Sanchez had 
earlier reported that 50ug is more efficacious than 
1925ug tablet . It is worth noting that misoprostol 
(synthetic prostaglandin E1 analogue) is 
available in 200ug tablets and smaller doses are 
obtained by breaking into pieces which may not 
be accurate. The study also reports that the 
decision for the use of misoprostol for IOL was 
taken at the consultant level (59.5%) as against 
2.4% at the level of the resident, while in about 
38% the decision could be taken at either level. 
Misoprostol is equally used for other indications 
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Person                                        Number                        %
Consultant                                      25                            59.5
Resident                                          2                               4.8 
Both                                                14                             33.3
N/R                                                 1                               2.4
                     
42                           100
Method                                             Number                          %
Misoprostol                                             9                             24.4
Foley’s catheter                            4                              9.5  
Misoprostol & fol.catheter                     14                            33.3  
Misoprostol & membrane sweeping      13                            31.0





Other indications for misoprostol used
 
Indication                                                  Number                        %
PPH                                                             21      
                           
50
Medication abortion                                    4                                   9.5
Incomplete abortion                                    1                                   2.4
IUFD                             
                              
2                                   4.8
PPH & med. Abortion                                 2                                   4.8 
PPH & incomp abortion                              1                                   2.4
N/R                                                              11                                 26.2
100
Complications    Number (n=42)                              
%
*Still birth                                                     12                             28.6
*Fetal distress                                               23   
                                
54.8
*Uterine hyper tonus                                     19                                45.2 
*Ruptured uterus                                          22                                 52.4
*Maternal pyrexia                                         13                                   31
N/R                                                               3                                7.1
* Multiple responses.
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like cervical ripening, medication abortion, 
missed abortion and control of postpartum 
haemorrhage as widely use elsewhere. 
Complication rate of between 28.6% - 54.8% of 
Fetal distress, uterine hyper tonus, uterine rupture, 
maternal pyrexia and stillbirth either alone or in 
combination were encountered during the course 
of their practiced, this finding is the general 
observed adverse outcome of misoprostol use as 
4, 20, 21
reported from many studies .  Use of 
misoprostol for IOL may not be better substitute 
for Oxytocin infusion neither is it better than 
membrane sweeping or Foleys catheter for 
ripening of cervix if this complications are put into 
22, 23perspective . Use of misoprostol as single agent 
for cervical ripening is also common, 24.4% 
compared to 33.3% for misoprostol with Foleys 
catheter, 31% misoprostol with membrane 
sweeping, while Foleys catheter alone is only used 
by less than 10% of the respondents. Digital 
stretching of fetal membrane for cervical ripening 
is a common practice although largely 
22unreported .
The ease of administration, availability low cost, 
and its efficacy despite disastrous consequences 
may be the main motivation for its widespread use. 
Fifty percent of the respondents also use this drug 
for the control of postpartum haemorrhage, while 
about 26% use it for PPH and incomplete abortion. 
However use of misoprostol in abortion related 
condition is very low, this is a surprise finding. It is 
a well known fact that pregnancy termination in 
most countries is illegal except where the mother's 
life is in danger or the fetus not viable or has major 
congenital abnormality. The observed low 
incidence for pregnancy termination may 
therefore be an under reporting. Further most 
recent survey by IPAS (Nigeria) of major 
pharmaceuticals outlets indicate that some of the 
drugs are probably dispensed without 
24prescription .
All the respondents recorded some major 
complications associated with misoprostol use as 
highlighted by the manufacturers. This is a major 
source of concern. Maternal and fetal death and 
ruptured uterus are particularly worrisome. Since 
this drug is not available in smaller dosage 
preparation, it's usually broken into pieces to 
approximate the doses. This is also another set 
back for its use in ripening of the cervix and IOL 
especially that incidences of complications 
increases with dosage.
It is absolutely necessary that this drugs are 
available in smaller doses and its use strictly 
regulated including close monitoring of patient 
after administration when use for ripening of the 
cervix and induction of labour.
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